Search

Search Constraints

You searched for: Author/Creator Cohen, Oliver C.

Search Results

1. Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse. (20th November 2018)

2. Cardiac Magnetic Resonance–Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. (20th April 2021)

3. Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single‐centre experience. Issue 3 (22nd March 2021)

4. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. (13th September 2020)

5. Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre. (2nd December 2020)

6. Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre. (2nd December 2020)

7. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis. (2nd July 2020)

8. The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre. (2nd October 2022)

9. The value of screening biopsies in light‐chain (AL) and transthyretin (ATTR) amyloidosis. (23rd June 2020)

10. Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis. (26th January 2020)